Browsing by Author Xie, Lu

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Showing results 1 to 20 of 35 next >
Issue Date Title Author(s)
2019 Anlotinib and irinotecan for advanced Ewing sarcoma after failure of standard therapy: A multicenter, two-cohort, single-arm, open label, phase Ib/II trial (NCT03416517). Xu, Jie;Xie, Lu;Guo, Wei;Tang, Xiaodong;Yang, Rongli;Yan, Taiqiang;Liu, Kuisheng;Gu, Jin
Mar-2021 Anlotinib, Vincristine, and Irinotecan for Advanced Ewing Sarcoma After Failure of Standard Multimodal Therapy: A Two-Cohort, Phase Ib/II Trial Xu, Jie;Xie, Lu;Sun, Xin;Liu, Kuisheng;Tang, Xiaodong;Yan, Taiqiang;Yang, Rongli;Guo, Wei;Gu, Jin
2020 Anorexia, Hypertension, Pneumothorax, and Hypothyroidism: Potential Signs of Improved Clinical Outcome Following Apatinib in Advanced Osteosarcoma Xie, Lu;Xu, Jie;Sun, Xin;Tang, Xiaodong;Yan, Taiqiang;Yang, Rongli;Guo, Wei
2017 Anti-angiogenesis target therapy for advanced osteosarcoma Xie, Lu;Ji, Tao;Guo, Wei
2018 Apatinib for advanced osteosarcoma after failure of standard multimodal therapy: An open label phase 2 clinical trial. Xie, Lu;Xu, Jie;Sun, Xin;Tang, Xiaodong;Yan, Taiqiang;Yang, Rongli;Guo, Wei
2019 Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial Xie, Lu;Xu, Jie;Sun, Xin;Tang, Xiaodong;Yan, Taiqiang;Yang, Rongli;Guo, Wei
2018 Apatinib for advanced sarcoma: results from multiple institutions' off-label use in China Xie, Lu;Guo, Wei;Wang, Ye;Yan, Taiqiang;Ji, Tao;Xu, Jie
2020 Apatinib for Treatment of Inoperable Metastatic or Locally Advanced Chondrosarcoma: What We Can Learn About the Biological Behavior of Chondrosarcoma from a Two-Center Study Xie, Lu;Xu, Jie;Sun, Xin;Liu, Kuisheng;Li, Xiaowei;He, Fangzhou;Liu, Xinyu;Gu, Jin;Lv, Zhe;Yang, Rongli;Tang, Xiaodong;Yan, Taiqiang;Li, Dasen;Yang, Yi;Dong, Sen;Sun, Kunkun;Shen, Danhua;Guo, Wei
2020 Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial Xie, Lu;Xu, Jie;Sun, Xin;Guo, Wei;Gu, Jin;Liu, Kuisheng;Zheng, Bingxin;Ren, Tingting;Huang, Yi;Tang, Xiaodong;Yan, Taiqiang;Yang, Rongli;Sun, Kunkun;Shen, Danhua;Li, Yuan
2019 Apatinib plus camrelizumab (SHR-1210) for unresectable high-grade osteosarcoma (APFAO) progressing after chemotherapy: A prospective, open label, phase II trial. Xie, Lu;Guo, Wei;Xu, Jie;Sun, Xin;Liu, Kuisheng;Zheng, Bingxin;Ren, Ting;Huang, Yi;Tang, Xiaodong;Yan, Taiqiang;Yang, Rongli;Sun, Kunkun;Shen, Danhua;Li, Yuan
20-May-2021 Apatinib plus ifosfamide and etoposide (IE) versus IE chemotherapy alone for relapsed or refractory osteosarcoma. Xie, Lu;Guo, Wei;Xu, Jie;Gu, Jin;Tang, Xiaodong;Li, Yuan;Sun, Kunkun
Jul-2021 Apatinib plus ifosfamide and etoposide for relapsed or refractory osteosarcoma: A retrospective study in two centres Xie, Lu;Xu, Jie;Sun, Xin;Li, Xiaowei;Liu, Kuisheng;Liang, Xin;Zhou, Zuli;Zhuang, Hongqing;Sun, Kunkun;Wu, Yiming;Gu, Jin;Guo, Wei
1-Jun-2022 Clinical implications of next-generation sequencing on pediatric solid tumors. Guo, Wei;Xie, Lu;Xu, Jie;Chen, Lijuan;Wang, Liwei;Wang, Aodi;Wang, Mingmin;Dong, Xiaowei;Mei, Lei;Chen, Hui;Yuan, Shaohua;Wang, Kai
7-Apr-2021 The Clinical Implications of Tumor Mutational Burden in Osteosarcoma Xie, Lu;Yang, Yufei;Guo, Wei;Che, Dongxue;Xu, Jie;Sun, Xin;Liu, Kuisheng;Ren, Tingting;Liu, Xingyu;Yang, Yi;Ji, Tao;Tang, Xiaodong
31-Mar-2021 Complete remission of metastatic osteosarcoma using combined modality therapy: a retrospective analysis of unselected patients in China Xie, Lu;Xu, Jie;Li, Xiaowei;Zhou, Zuli;Zhuang, Hongqing;Sun, Xin;Liu, Kuisheng;Liu, Xingyu;Sun, Kunkun;Wu, Yiming;Gu, Jin;Guo, Wei
15-Jun-2022 Distinct genetic features between osteosarcomas firstly metastasizing to bone and to lung Xie, Lu;Cai, Zhenyu;Tang, Xiaodong;Guo, Wei;Meng, Fanfei;Zhang, Xin;Shi, Xiaoliang;Pang, Fei
2022 Effectiveness and Tolerability of Anlotinib Plus PD-1 Inhibitors for Patients with Previously Treated Metastatic Soft-Tissue Sarcoma Sun, Xin;Xu, Jie;Xie, Lu;Guo, Wei
20-May-2021 Efficacy and safety of anlotinib combined with liposomal doxorubicin in first-line treatment of advanced soft-tissue sarcoma. Sun, Xin;Guo, Wei;Zhang, Ranxin;Xie, Lu;Xu, Jie
20-May-2021 Efficacy and safety of anlotinib plus TQB2450 in patients with advanced soft tissue sarcoma: A multicenter, single armed, phase 1b trial. Liu, Jiayong;Fan, Zhengfu;Guo, Wei;Gao, Tian;Li, Shu;Xu, Jie;Bai, Chujie;Xue, Ruifeng;Zhang, Lu;Xie, Lu;Tan, Zhichao
Apr-2022 An evaluation of the response to neoadjuvant chemotherapy for osteosarcoma of extremities: PERCIST versus RECIST 1.1 criteria after long-term follow-up Xu, Jie;Li, Yuan;Xie, Lu;Sun, Xin;Cai, Zhenyu;Wang, Shidong;Wang, Qian;Sun, Kunkun;Guo, Wei
Showing results 1 to 20 of 35 next >